Evommune Inc（EVMN）资讯与事件EVMNEvommune Inc

Evommune CEO Anticipates EVO756 Phase 2b Data Release

"There are still no first-line oral options for patients suffering with AD that combine lesion control, itch relief and tolerability. That gap is where we believe EVO756 can make a difference, as it targets neurogenic mast cell biology and non-histaminergic itch. We are excited to deliver top-line Phase 2b data next month. We also believe the underlying biology and market opportunity are especially compelling in migraine prophylaxis and that EVO756 could define the next wave of preventative treatments. We are very excited to have the Phase 2b trial now underway and expect top-line data next year," said Luis Pena, President and Chief Executive Officer at Evommune. "Taken together, these milestones reflect the continued execution of our mission-driven approach to developing transformative therapies for people living with immune-mediated diseases."

Evommune Initiates Phase 2b Trial for EVO756

Evommune announced the first patient was dosed in its Phase 2b clinical trial evaluating EVO756, for the prophylactic treatment of migraine. "Initiating this migraine trial is an exciting milestone for Evommune and for patients who remain inadequately served by current preventive therapies," said Luis Pena, President and Chief Executive Officer of Evommune. "While the preventive migraine market has seen progress, innovation has largely been limited to a single target and a meaningful proportion of patients continue to experience inadequate relief. A substantial opportunity remains for a front-line oral therapy with a differentiated mechanism. EVO756's dual-action biology, targeting both human trigeminal neurons and meningeal mast cells, combined with its multi-neuropeptide coverage and mechanistic breadth could translate across a wide range of migraine patients, including those who have not responded adequately to CGRP inhibitors. We look forward to reporting top-line data from this trial in 2027."

Major Averages Finish Broadly Higher as Investors Await Middle East News

The major averages finished broadly higher as investors await news out of the Middle East. President Trump said the U.S. and Iran will meet to negotiate after days of strikes as the market shifts focus from geopolitics back toward macro data. Investors are watching labor market releases, including the JOLTS report and Thursday's payroll report, for clues on the Federal Reserve path. Markets continue to weigh a resilient economy against concerns that sticky inflation could keep the Fed more restrictive than expected.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:SpaceXwillon July 7Comcastplans to separate intothrough a tax-free spin-off of NBCUniversal and SkySpaceXand Charterhave discussed partnering on a mobile phone offering,Verizonand BT Groupwilland combine international operationsRocket LabIridiumfor $54 per share in a cash and stock transaction2. WALL STREET CALLS:Robloxto Buy at AreteAdobeto Neutral at Phillip SecuritiesDoximityto Underperform from Buy at BofAQuantinuumwith mostly Buy or equivalent ratings as Wall Street rolled out coverageCoverage of Liftoff Mobilewas alsowith mostly bullish ratings3. AROUND THE WEB:Carlislehas made unsolicited offers for Owens Corning, WSJ reportsEli Lillyand Regeneronare among the first selections for the FDA's PreCheck program, CNBC reportsAmazoncould pay more for Anthropic's technology, The Information reportsIntelis gaining momentum from the AI boom and new partnerships with Nvidia, Apple, and Elon Musk's Terafab project, but its long-term future depends on proving its new 14A manufacturing process can succeed and help restore U.S. chip production, New York Times reportsSamsungand SK Hynix intend to invest over $500B in a new chip-making hub in South Korea, WSJ says4. MOVERS:Repay Holdingsincreases after Forager Fundthe company for $5.25 per shareFuelCellgains after B. Rileythe stock to BuyPalisade Biohigher afterto start its ulcerative colitis studyEvommunelower after Phase 2b trial of EVO756Larimar Therapeuticsfalls afterof its rolling BLA for nomlabofusp5. EARNINGS/GUIDANCE:GameStopprovidedPerfect Moment, with EPS and revenue higher year-over-yearKolibri Global EnergyprovidedNiketoon June 30Constellation Brandstoon June 30INDEXES:The Dow rose 306.63, or 0.59%, to 52,182.74, the Nasdaq gained 522.53, or 2.07%, to 25,820.15, and the S&P 500 advanced 86.41, or 1.18%, to 7,440.43.